CoChat

Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes

Open access
Buckingham, Bruce, Beck, Roy W., Ruedy, Katrina J., Cheng, Peiyao, Kollman, Craig, Weinzimer, Stuart A., DiMeglio, Linda A., Bremer, Andrew A., Slover, Robert, Tamborlane, William V., Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups · 2013 · Diabetes Care
Cited by 71

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To assess effectiveness of inpatient hybrid closed-loop control (HCLC) followed by outpatient sensor-augmented pump (SAP) therapy initiated within 7 days of diagnosis of type 1 diabetes on the preservation of β-cell function at 1 year. RESEARCH DESIGN AND METHODS: Sixty-eight individuals (mean age 13.3 ± 5.7 years; 35% female, 92% Caucasian) were randomized to HCLC followed by SAP therapy (intensive group; N = 48) or to the usual-care group treated with multiple daily injections or insulin pump therapy (N = 20). Primary outcome was C-peptide concentrations during mixed-meal tolerance tests at 12 months. RESULTS: Intensive-group participants initiated HCLC a median of 6 days after diagnosis for a median duration of 71.3 h, during which median participant mean glucose concentration was 140 mg/dL (interquartile range 134–153 mg/dL). During outpatient SAP, continuous glucose monitor (CGM) use decreased over time, and at 12 months, only 33% of intensive participants averaged sensor use ≥6 days/week. In the usual-care group, insulin pump and CGM use were initiated prior to 12 months by 15 and 5 participants, respectively. Mean HbA1c levels were similar in both groups throughout the study. At 12 months, the geometric mean (95% CI) of C-peptide area under the curve was 0.43 (0.34–0.52) pmol/mL in the intensive group and 0.52 (0.32–0.75) pmol/mL in the usual-care group (P = 0.49). Thirty-seven (79%) intensive and 16 (80%) usual-care participants had a peak C-peptide concentration ≥0.2 pmol/mL (P = 0.30). CONCLUSIONS: In new-onset type 1 diabetes, HCLC followed by SAP therapy did not provide benefit in preserving β-cell function compared with current standards of care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc13-1074

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 71

Metadata

Authors
Buckingham, B., Beck, R. W., Ruedy, K. J., Cheng, P., Kollman, C., Weinzimer, S. A., DiMeglio, L. A., Bremer, A. A., Slover, R., Tamborlane, W. V., & Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups
Venue
Diabetes Care
Published
2013-11-13
Volume
36
Issue
12
Pages
4030-4035
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2028990915
Cited by
71
References
4
FWCI
6.37
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/dc13-1074
The paper
Buckingham, B., Beck, R. W., Ruedy, K. J., Cheng, P., Kollman, C., Weinzimer, S. A., DiMeglio, L. A., Bremer, A. A., Slover, R., Tamborlane, W. V., & Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups. (2013). Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc13-1074

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.